73/100B1,085.80
USD
26.55
(2.51%)
Market Closed
Last updated: · Delayed 15 min
Fair value935.50Plus+16%589Price 1,085.801,311
Q3 FY2027 · Earnings report
EPS estimate 10.94Revenue estimate 113.63B
Q3 FY2027 · Earnings report
EPS estimate 10.94Revenue estimate 113.63B
If you had invested in McKesson ago, it would be worth $7,921 today, against $4,048 in SPY and $6,247 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
73/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2026; the price as of today.
McKesson key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Growth stock · 5.8/10Growth 5.8 · Value 5.8 · Dividend 2.0
- Day range
- 1,061.28 – 1,087.11
- 52-week range
- 723.68 – 1,121.50
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 125.36B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 27.81
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.84
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 39.05
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 0.35%
- EPS growth forecast (FY2027)
- +15.3%
- Volume
- 38,524
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.28
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 64.3/100Environment 64 · Social 57 · Governance 72
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler
- Employees
- 42K
- Website
- mckesson.com
- IPO date
- 10 Nov 1994
McKesson earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q3 FY2027
EPS estimate
10.94 USD
Revenue estimate
113.63B USD
Last quarter · Q2 FY2027
EPS11.68Beat +9.0%Revenue110.96BBeat +1.0%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2028 | 12.67 | — | — | +15.84% | 119.62B | — | — | +5.27% | |
| Q2 FY2028 | 12.70 | — | — | +8.77% | 116.24B | — | — | +4.76% | |
| Q1 FY2028 | 11.57 | — | — | +16.50% | 112.01B | — | — | +6.29% | |
| Q3 FY2027 | 10.94 | — | — | +17.13% | 113.63B | — | — | +7.04% | |
| Q2 FY2027 | 10.72 | 11.68 | +8.96% | +18.46% | 109.90B | 110.96B | +0.97% | +7.57% | |
| Q1 FY2027 | 9.56 | 9.93 | +3.87% | +20.22% | 103.88B | 105.38B | +1.45% | +7.72% | |
| Q4 FY2026 | 11.56 | 11.69 | +1.12% | +15.51% | 101.35B | 96.30B | -4.98% | +6.02% | |
| Q3 FY2026 | 9.17 | 9.34 | +1.85% | +16.31% | 105.80B | 106.16B | +0.34% | +11.40% | |
| Q2 FY2026 | 9.03 | 9.86 | +9.19% | +39.46% | 104.14B | 103.15B | -0.95% | +10.14% | |
| Q1 FY2026 | 8.14 | 8.26 | +1.47% | +4.82% | 96.18B | 97.83B | +1.71% | +23.39% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2029 | 58.54 | — | — | +13.96% | 494.01B | — | — | +6.73% |
| FY2028 | 51.37 | — | — | +13.76% | 462.87B | — | — | +6.83% |
| FY2027 | 45.16 | — | — | +15.34% | 433.28B | — | — | +7.40% |
| FY2026 | 39.01 | 39.15 | +0.36% | +18.28% | 408.47B | 403.43B | -1.24% | +12.36% |
| FY2025 | 32.78 | 33.10 | +0.97% | +20.71% | 362.56B | 359.05B | -0.97% | +16.22% |
| FY2024 | 27.61 | 27.42 | -0.69% | +5.54% | 311.92B | 308.95B | -0.95% | +11.65% |
| FY2023 | 25.96 | 25.98 | +0.09% | +9.67% | 275.91B | 276.71B | +0.29% | +4.83% |
McKesson analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
998.57 USD
-8.03%
Analysts' 1-year price targets range from 845.00 to 1,200.00, with an average of 998.57.
Past year
1-year forecast
Strong sellStrong buy
Buy
11 ratings
| Buy | 8 | |
| Hold | 3 | |
| Sell | 0 |
12-month price target
| Highest target | 1,200.00 |
| Average target | 998.57 |
| Lowest target | 845.00 |
| Current price | 1,085.80 |
McKesson valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 27.81
- Forward P/E (FY2027)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 24.04
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 0.30
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 17.22
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
125.36B USD
+
Total debt
11.16B USD
−
Cash and short-term investments
6.53B USD
=
Enterprise value
130.00B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
McKesson against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2022 to FY2026: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Stryker, Bristol-Myers Squibb, Vertex Pharmaceuticals, HCA Healthcare, CVS Health, and Danaher, the US Healthcare companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median27.815.146.9
- Gross marginBelow its median3.6%3.5%4.8%Against its peers: 7 of 7Peers' median 62.4%
- Operating marginAbove its median1.6%1.0%1.6%Against its peers: 7 of 7Peers' median 20.2%
- Net marginAbove its median1.2%0.4%1.3%Against its peers: 6 of 7Peers' median 13.8%
- Free cash flow marginBelow its median1.3%1.2%1.7%Against its peers: 7 of 7Peers' median 19.2%
- Revenue growthAbove its median12.4%4.8%16.2%Against its peers: 1 of 7Peers' median 7.5%
- EPS growthAbove its median49.2%-10.6%246.3%Against its peers: 1 of 5Peers' median 1.8%
- Debt to EBITDALowest in 5 years1.20×1.20×2.63×Against its peers: 2 of 7Peers' median 2.87×
- Current ratioLowest in 5 years0.850.850.95Against its peers: 5 of 7Peers' median 1.56
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
McKesson growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 418.79B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 4.70B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 3.67%
- Operating margin
- 1.62%
- Net margin
- 1.12%
Revenue / Net income
Revenue Net income Net margin
McKesson revenue breakdown
By product
FY2026
83.4%North American Pharmaceutical12.0%Oncology And Multispecialty2.9%Medical-Surgical Solutions1.4%Prescription Technology Solutions
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| North American Pharmaceutical | 336.65B | 83.4% | — |
| Oncology And Multispecialty | 48.42B | 12.0% | — |
| Medical-Surgical Solutions | 11.51B | 2.9% | +1.1% |
| Prescription Technology Solutions | 5.81B | 1.4% | +11.3% |
| Other | 1.04B | 0.3% | — |
By region
FY2020
83.4%United States16.6%International
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 192.71B | 83.4% | +9.3% |
| International | 38.34B | 16.6% | +0.8% |
How McKesson makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
North American Pharmaceutical336.65B 83.4%
Oncology And Multispecialty48.42B 12.0%
Medical-Surgical Solutions11.51B 2.9%
Prescription Technology Solutions5.81B 1.4%
Other1.04B 0.3%
Revenue403.43B 100.0%
Cost of revenue388.88B 96.4%
Gross profit14.55B 3.6%
Research and development103.00M 0.0%
Other operating expenses7.99B 2.0%
Operating income6.45B 1.6%
Tax1.10B 0.3%
Other expense590.00M 0.1%
Net income4.76B 1.2%
FY2026, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2026, in USD. Each band is as wide as its money; the percentage is its share of revenue.
McKesson dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 3.76 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 0.35%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 11.11%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 19
- Frequency
- Quarterly
- Next payment
- 0.94 USD
- Next ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 1 Dec 2026
- Next payment date
- 4 Jan 2027
Dividends per share
McKesson financial health
- Cash and short-term investments
- 6.53B USD
- Total debt
- 11.16B USD
- Net cash
- -4.63B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 6.91B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 0.90
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 7 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 5.82
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
McKesson ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 87.13%
- Institutional holders
- 2,089 (-24)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.94%
Who owns the shares
Institutions 87.1% Others 12.9%
As of 30 Jun 2026
Shares free to trade
Free float 115.38M shares ·99.9% Closely held 74.12K shares ·0.1%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 3 | 398.00 | 2.61K |
| Q3 2026 | 0 | 3 | 3.14K | 8.88K |
| Q2 2026 | 0 | 8 | 100.73K | 71.05K |
| Q1 2026 | 0 | 6 | 5.26K | 11.28K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: McKesson Corp
Sector: Healthcare
Industry: Medical - Distribution
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.